Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8N4J0
UPID:
CARME_HUMAN
Alternative names:
-
Alternative UPACC:
Q8N4J0; Q7Z383; Q8N7C5
Background:
Carnosine N-methyltransferase is a pivotal enzyme that catalyzes the formation of anserine from carnosine, playing a crucial role in vertebrate skeletal muscles. It specifically targets L-histidine-containing di- and tripeptides, including Gly-Gly-His and homocarnosine, for methylation.
Therapeutic significance:
Understanding the role of Carnosine N-methyltransferase could open doors to potential therapeutic strategies. Its involvement in muscle physiology suggests its potential in treating muscle-related disorders.